RIP1 inhibitor GSK547 is primarily used in research and therapeutic contexts targeting inflammatory and autoimmune diseases. It works by inhibiting the receptor-interacting protein 1 (RIP1) kinase, which plays a critical role in regulating cell death and inflammation. This makes it a promising candidate for treating conditions like rheumatoid arthritis, psoriasis, and inflammatory bowel disease, where excessive inflammation is a key factor. Additionally, it is being explored in oncology to enhance the effectiveness of cancer therapies by modulating cell death pathways. Its application extends to neuroprotection studies, particularly in diseases like ALS and Alzheimer’s, where RIP1-mediated inflammation contributes to disease progression. Overall, GSK547 serves as a valuable tool in understanding and potentially treating diseases driven by dysregulated inflammation and cell death.